http://orcid.org/0000-0001-5420-279X
Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zhen Ruan, Lisong Yang, Honghao Shi, Xiaomeng Yue, Yao Wang, Miaoying Liang & Hao Hu. (2021) The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research 21:2, pages 221-233.
Read now
Read now
Peng Men, Tianbi Liu & Suodi Zhai. (2020) Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China. Diabetes, Metabolic Syndrome and Obesity 13, pages 2823-2831.
Read now
Read now
Articles from other publishers (15)
Henrik Vitus Bering Laursen, Emmelie Ploug Jørgensen, Peter Vestergaard & Lars Holger Ehlers. (2023) A Systematic Review of Cost-Effectiveness Studies of Newer Non-Insulin Antidiabetic Drugs: Trends in Decision-Analytical Models for Modelling of Type 2 Diabetes Mellitus. PharmacoEconomics.
Crossref
Crossref
Marc Evans, Sasha Berry, Samuel J. P. Malkin, Barnaby Hunt & Abheet Sharma. (2023) Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK. Diabetes Therapy 14:6, pages 1005-1021.
Crossref
Crossref
Irene Romera, Miriam Rubio-de Santos, Sara Artola, Carmen Suárez Fernández & Ignacio Conget. (2023) GLP-1 RAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice. Advances in Therapy 40:4, pages 1418-1429.
Crossref
Crossref
Valentina Velkoska Nakova, Zoran Nakov, Stojka Dokuzova, Tatjana Prosheva & Brankica Krstevska. (2023) Efficacy and Safety of Empagliflozine and Semaglutide (Once Weekly) in T2DM Patients in Shtip. PRILOZI 44:1, pages 71-77.
Crossref
Crossref
Marc Evans, Barrie Chubb, Samuel J. P. Malkin, Sasha Berry, Jack Lawson & Barnaby Hunt. (2022)
Once‐weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the
UK
: A long‐term cost‐effectiveness analysis based on
SUSTAIN
11
. Diabetes, Obesity and Metabolism 25:2, pages 491-500.
Crossref
Crossref
Lei Liu, Zhen Ruan, Carolina Oi Lam Ung, Yawen Zhang, Yang Shen, Sheng Han, Ruxu Jia, Jingtao Qiao, Hao Hu & Lixin Guo. (2022) Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China. Diabetes Therapy 14:1, pages 93-107.
Crossref
Crossref
Zhen Ruan, Carolina Oi Lam Ung, Yang Shen, Yawen Zhang, Weihao Wang, Jingyi Luo, Huimin Zou, Yan Xue, Yao Wang, Hao Hu & Lixin Guo. (2022) Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China. Diabetes Therapy 13:10, pages 1737-1753.
Crossref
Crossref
Sara Stafford, Peter G. Bech, Adam Fridhammar, Nino Miresashvili, Andreas Nilsson, Michael Willis & Aiden Liu. (2022) Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. Applied Health Economics and Health Policy 20:4, pages 543-555.
Crossref
Crossref
Josep Franch-Nadal, Samuel J. P. Malkin, Barnaby Hunt, Virginia Martín, María Gallego Estébanez & Josep Vidal. (2022) The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Advances in Therapy 39:7, pages 3180-3198.
Crossref
Crossref
Lars H. Ehlers, Mark Lamotte, Mafalda C. Ramos, Susanne Sandgaard, Pia Holmgaard, Malene M. Kristensen & Niels Ejskjaer. (2022) The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark. Diabetes Therapy 13:3, pages 489-503.
Crossref
Crossref
Mari Pesonen, Eila Kankaanpää & Virpi Jylhä. (2022) Adverse drug events in cost-effectiveness analyses of interventions for diabetic conditions: a scoping review protocol. JBI Evidence Synthesis 20:12, pages 3058-3066.
Crossref
Crossref
Margaret F Zupa, Ronald A Codario & Kenneth J Smith. (2021) Cost–effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes. Journal of Comparative Effectiveness Research 10:15, pages 1133-1141.
Crossref
Crossref
Kevin Fernando, Stephen C. Bain, Patrick Holmes, Philip Newland Jones & Dipesh C. Patel. (2021) Glucagon-Like Peptide 1 Receptor Agonist Usage in Type 2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review. Diabetes Therapy 12:9, pages 2267-2288.
Crossref
Crossref
Virginia Martín, Josep Vidal, Samuel J. P. Malkin, Nino Hallén & Barnaby Hunt. (2020) Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in Therapy 37:10, pages 4427-4445.
Crossref
Crossref
Yilin Yoshida, Xi Cheng, Hui Shao, Vivian A. Fonseca & Lizheng Shi. (2020) A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. Current Diabetes Reports 20:4.
Crossref
Crossref